PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics
Version 1
: Received: 17 October 2018 / Approved: 17 October 2018 / Online: 17 October 2018 (11:08:56 CEST)
How to cite:
Biswas, T.; Jindal, C.; Fitzgerald, T.; Efird, J. Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics. Preprints2018, 2018100383. https://doi.org/10.20944/preprints201810.0383.v1
Biswas, T.; Jindal, C.; Fitzgerald, T.; Efird, J. Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics. Preprints 2018, 2018100383. https://doi.org/10.20944/preprints201810.0383.v1
Biswas, T.; Jindal, C.; Fitzgerald, T.; Efird, J. Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics. Preprints2018, 2018100383. https://doi.org/10.20944/preprints201810.0383.v1
APA Style
Biswas, T., Jindal, C., Fitzgerald, T., & Efird, J. (2018). Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics. Preprints. https://doi.org/10.20944/preprints201810.0383.v1
Chicago/Turabian Style
Biswas, T., Timothy Fitzgerald and Jimmy Efird. 2018 "Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics" Preprints. https://doi.org/10.20944/preprints201810.0383.v1
Abstract
The aim of this study was to examine pathologic complete response (pCR) and overall survival (OS) of patients diagnosed with non-metastatic inflammatory breast cancer (IBC). A total of N=8,550 cases undergoing surgery were identified between 2004-2013, using the National Cancer Database (NCDB). Patients were grouped into 4 biologic subtypes (HR+/HER2-, HR+/HER2+, HR-/HER2+, HR-/HER2-). The median age at diagnosis was 56 years. On average, women were followed for 3.7 years [interquartile range=3.0]. The majority were white (80%), had private health insurance (50%), and presented with poorly differentiated tumors (57%). Approximately 46% of the cancers were >5cm. Most patients underwent mastectomy (94%) and received radiotherapy (71%). Differences by biologic subtypes were observed for grade, lymph node invasion, race, and tumor size (p<.0001). Compared with non-pCR (54%), patients experiencing pCR had superior 5-year survival (77%) (p<.0001). Survival was poor for triple-negative (TN) tumors (37%) vs. other biologic subtypes (60%) (p<.0001). On multivariable analysis, TN-IBC, positive margins, and not receiving either chemotherapy, hormonal therapy or radiotherapy were independently associated with poor 5-year survival (p<.0001). In this large multicentric analysis of IBC, categorized by biologic subtypes, we observed significant differential tumor, patient and treatment characteristics, and OS.
Keywords
Biologic subtypes; diagnosis; inflammatory breast cancer; pCR; survival
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
